AUROPHARMA2023-10-012023-12-31 AUROPHARMA2023-10-012023-12-31 AUROPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2023-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NOTLISTED Aurobindo Pharma Limited Equity 2023-04-01 2024-03-31 2024-02-10 2024-02-01 INR Millions Third quarter 15:00:00 17:15:00 2024-02-10 2024-02-10 Not applicable Single segment Pharmaceutical Products 2023-10-01 2023-12-31 Unaudited Standalone 26920300000.00 3311300000.00 30231600000.00 14659300000.00 1550900000.00 -597600000.00 2480800000.00 612500000.00 643500000.00 4010000000.00 23359400000.00 6872200000.00 0.00 6872200000.00 1369500000.00 -735100000.00 634400000.00 0.00 6237800000.00 0.00 0.00 0.00 0.00 6237800000.00 -2900000.00 6234900000.00 6234900000.00 0.00 585900000.00 1 10.65 10.65 0.00 0.00 10.65 10.65 NOTES: 1.The above standalone financial results of Aurobindo Pharma Limited ( the Company ) has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2.The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 10, 2024. The results for the quarter and nine months ended December 31, 2023 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2023. 3.The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, Operating Segment . 4.The Board of Directors of the Company at its meeting held on February 9, 2023 and April 1, 2023 approved the transfer of certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (APPL) on a going concern basis by way of slump sale, subject to receipt of requisite regulatory approvals. Consequent to receipt of such approvals, the Company transferred the aforementioned API units to APPL with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 Non-Current Assets Held for Sale and Discontinued Operations , in the standalone financial results for all the periods have been suitably presented. Key financials information of discontinued Operations(Rs. in million): Particulars Quarter ended Nine months ended Year Ended 31.12.2023 30.09.2023 31.12.2022 31.12.2023 31.12.2022 31.03.2023 Total Income - 13081.1 10,720.7 24,183.5 31,766.6 43,260.8 Total expenses - 12,596.7 11,046.9 23,458.6 32550.0 43,458.4 Profit/(loss) before tax - 484.4 (326.2) 724.9 (783.4) (197.6) Total tax expense - 123.5 (85.0) 184.5 (208.7) (47.0) Net profit/(loss) for the period - 360.9 (241.2) 540.4 (574.7) (150.6) 5.The Board of Directors at their meeting held on February 10, 2024 declared an interim dividend of Rs.1.50 per equity share (Face value Re.1). By Order of the Board K.Nithyananda Reddy Vice Chairman & Managing Director DIN-01284195 Place: Hyderabad Date: February 10, 2024 Single segment 2023-04-01 2023-12-31 Unaudited Standalone 77516100000.00 4930900000.00 82447000000.00 43595200000.00 1863900000.00 -1031300000.00 7316500000.00 1295300000.00 1897700000.00 11279300000.00 66216600000.00 16230400000.00 0.00 16230400000.00 3904200000.00 -888100000.00 3016100000.00 0.00 13214300000.00 724900000.00 184500000.00 540400000.00 0.00 13754700000.00 -13300000.00 13741400000.00 13741400000.00 0.00 585900000.00 1 22.55 22.55 0.92 0.92 23.47 23.47 Other expenses 4010000000.00 Other expenses 11279300000.00 -3900000.00 -17800000.00 -1000000.00 -4500000.00 0.00 0.00